0001628280-26-030917
SEC filingRevenue declined sharply year-over-year, driving a swing from strong profitability in Q1 FY2025 to an operating loss and net loss in Q1 FY2026; this reflects the structural transition in commercial responsibility for Nuvaxovid™, while gross margin remained stable at 78.0%.
Revenue for Q1 FY2026 totaled $139.5 million, a 79.1% decrease from $666.7 million in Q1 FY2025. This decline was primarily due to the reduction in direct sales of Nuvaxovid™ following the transition of commercial leadership to Sanofi — a strategic realignment that shifted Novavax’s role toward supply and licensing. Gross profit decreased to $108.8 million (down 83.3% year-over-year), but gross margin remained stable at 78.0%, reflecting disciplined manufacturing execution and unchanged unit-level economics despite lower volume. The increase in cost of sales was driven by higher supply sales of COVID-19 vaccine, adjuvant, and other materials to partners — not operational inefficiency or inventory write-downs.
Operating income declined to a loss of $15.4 million, compared to income of $515.5 million in Q1 FY2025. This swing reflects the substantial revenue contraction, partially offset by reductions in selling, general, and administrative (SG&A) expenses. Management attributes the SG&A decline to cost containment measures, including a deliberate reduction in the global commercial footprint and administrative infrastructure. Net income followed a similar trajectory, falling to a loss of $9.5 million (diluted EPS: -$0.06) from income of $518.6 million (EPS: $2.93). The year-over-year change in net income is directly attributable to the decline in total revenue, as noted in management’s discussion.
Net cash used in operating activities improved significantly to $32.4 million in Q1 FY2026, compared to $185.5 million used in Q1 FY2025. This improvement reflects both the timing and composition of cash outflows associated with the company’s evolving business model — specifically, lower cash requirements tied to commercial operations and infrastructure. Management explicitly links this improvement to cost containment initiatives, including the reduction in global commercial presence and administrative overhead. The stability of gross margin and the narrowing of operating cash outflow underscore the effectiveness of these structural adjustments in preserving liquidity during the transition phase.